Background: Infant leukaemia (IL) is extremely rare with fewer than 150 cases occurring each year in the United States. Little is known about its causes. However, recent evidence supports a role of de novo mutations in IL aetiology. Parental age has been associated with several adverse outcomes in offspring, including childhood cancers. Given the role of older parental age in de novo mutations in offspring, we carried out an analysis of parental age and IL. Methods: We evaluated the relationship between parental age and IL in a case-control study using registry data from New York, Minnesota, California, Texas, and Washington. Records from 402 cases [219 acute lymphoblastic leukaemia (ALL), 131 acute myeloid leukaemia (AML), and 52 other] and 45 392 controls born during 1981-2004 were analysed. Odds ratios (OR) and 95% confidence intervals (CI) were calculated by logistic regression. Estimates were adjusted for infant sex, birth year category, maternal race, state, and mutually adjusted for paternal or maternal age, respectively. Results: Infants with mothers' age ≥40 years had an increased risk of developing AML (OR 4.80, 95% CI 1.80, 12.76). In contrast, paternal age <20 was associated with increased risk of ALL (OR 3.69, 95% CI 1.62, 8.41). Conclusion: This study demonstrates increased risk of infant ALL in relation to young paternal age. Given record linkage, there is little concern with recall or selection bias, although data are lacking on MLL gene status and other potentially important variables. Parent of origin effects, de novo mutations, and/or carcinogenic exposures may be involved in IL aetiology.
Leukaemia that occurs in infancy (<12 months of age) is distinct from leukaemia in older children. Infants with leukaemia are more often female (compared to~30% greater incidence in males overall for childhood leukaemia), have a nearly equal distribution of acute lymphoblastic (ALL) to acute myeloid leukaemia (AML) diagnosis (compared to about four times greater incidence of ALL in older children), 1 and have an increased frequency of somatic MLL gene rearrangements (50-80% of infant ALL and 34-50% of infant AML compared to approximately 6% and 14% for ALL and AML in older children, respectively). 2, 3 The MLL gene rearrangement in infant leukaemia is especially remarkable given that similar MLL rearrangements are observed in chemotherapy-related leukaemias (mostly, AML) associated with modalities that inhibit DNA topoisomerase II. 4 There have been a few epidemiological investigations of infant leukaemia, 5, 6 and there is some evidence that maternal exposure to DNA topoisomerase II inhibitors during pregnancy through diet and medications may play a causal role, especially for infant AML with MLL gene rearrangements. 7 Infants with leukaemia, especially ALL with MLL gene rearrangements, experience survival rates of <50%, which is considerably lower than childhood ALL overall which currently experiences over 80% 5-year survival. 1 As the causes of infant leukaemia are largely unknown, it is important to continue to study risk factors to understand the underlying aetiology. Recent observations show that there is a high burden of germline genetic variation in the MLL3 gene among infants with MLL-negative leukaemia. 8 In this study, 23 infant-mother pairs (12 ALL, 13 AML) underwent whole exome sequencing. MLL3 was a compound heterozygote in 100% of infants with AML and 50% of those with ALL, suggesting that germline mutations may be important for leukemogenesis in the absence of MLL rearrangements or a high burden of somatic mutations. While 47% of the germline variation in the infants could be tracked to maternal alleles, this study did not have paternal DNA available, but these results suggest that the additional germline variation is either of paternal or de novo origin (or both). Advanced parental age has been associated with several outcomes in offspring, including autism, 9 congenital abnormalities and syndromes, 10 and childhood cancers. 11 Given the role of older parental age in de novo mutations in offspring, and the potential role of parental age in gene rearrangements, we carried out an analysis of parental age and infant leukaemia in a population-based study using pooled data from five US states.
Methods
Childhood cancer cases were identified in the population-based cancer registries of California, Minnesota, New York (excluding New York City), Texas, and Washington; recent estimates show at least 95% case completeness. 12 Eligibility criteria, matching factors, and inclusion years have been published previously.
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Briefly, cases were classified according to the International Classification of Childhood Cancer 3rd edition. Controls were randomly selected from each state's birth certificates. Original datasets which were pooled for this study varied in case : control ratios that ranged from 1:1 to 10:1. Controls were matched to cases by birth year in all states; California and Texas additionally matched by sex. Individual matching was performed in California, while frequency matching was used for the other four states. Table 1 shows characteristics of original datasets which were pooled for this study.
Additional criteria were applied for consistency. As cases were permitted to be selected as controls for Minnesota and New York, we excluded them from the control group in this analysis. The California registry included cases diagnosed <28 days of age; these were excluded for consistency with the other states. For this analysis, we restricted cases to infants diagnosed with acute leukaemia before they reached 1 year of age. Our final dataset consisted of 402 infants diagnosed with acute leukaemia between the ages of 1 month and 1 year (219 ALL, 131 AML, and 52 other) and 45 392 controls.
Available birth record information included parental age, birthweight, gestational age, plurality, sex, birth order, birth year, and maternal race. California provided gestational age based on the last menstrual period (LMP) while the other four states calculated gestational age using LMP and a clinical estimate. We calculated gestational age using the LMP when available and, when LMP was unavailable, we used the clinical estimate of gestational age. Clinical estimate was used for 2749 (6%) of the births in our dataset.
Statistical analysis
Odds ratios (OR) and 95% confidence intervals (CI) were estimated by unconditional logistic regression (SAS version 9.4, SAS Institute, Cary, NC, USA); The association between parental age and infant leukaemia was analysed utilizing two methods. The first method was complete case analysis in which a total of 5547 controls and 72 cases were excluded due to missing maternal race, maternal age, paternal age, or sex (see Table 2 ). Due to the large number of records missing paternal age, our second method employed fully conditional specification (FCS) logistic regression multiple imputation procedures (PROC MI and PROC MIANALYZE) to impute paternal and maternal age. FCS is an iterative Markov chain Monte Carlo (MCMC) method wherein a model is specified for each partially observed variable conditional on all other variables, then missing values are imputed for the variable being fit. The method continues until the maximum number of iterations is reached, and the imputed values at the maximum iteration are saved to the imputed dataset. Forty iterations and ten imputation datasets were used. Missing paternal age was most prevalent among children of the youngest mothers: Of the 834 mothers aged 16 years or younger, 41.4% were missing paternal ages. By contrast, of the 45 463 mothers aged >16 years, 10.9% were missing paternal ages. The correlation between maternal and paternal age was lower in this age group (r ≤16 years = 0.11 vs. r ≥17 years = 0.74). To reduce any potential bias attributable to this distribution of missing data, we conducted a sensitivity analysis of the complete case method, restricting cases and controls to those with a maternal age ≥16 years. Finally, we conducted a sensitivity analysis excluding births prior to 1989 from Washington, as Down's syndrome was not recorded during those years. We also conducted a bias analysis to assess the impact of under-reporting of Down's syndrome cases in our dataset. We calculated the observed and expected numbers of Down's syndrome cases and reconstructed the dataset using maternal age to determine the probability that the infant had Down's syndrome, based on published maternal age-specific incidence rates, 13 taking into account the number of observed cases and assuming a sensitivity and specificity of 18% and 99%, respectively, for birth certificate reports of Down's syndrome. 14 To perform a single reconstruction, we conducted a Bernoulli trial for all subjects, based on their probabilities, to assign whether they were classified as a Down's syndrome case. We then subjected each reconstructed dataset to the logistic regression models, excluding the subjects classified as Down's syndrome cases in that iteration. We conducted 100 reconstructions. Utilizing these methods, we examined the association between parental age and infant leukaemia overall, as well as stratified by leukaemia type (ALL and AML) and by infant's age at diagnosis (1-5 months, 6-11 months).
Results
We did not observe any differences between cases and controls with regard to plurality, birthweight, or gestational age (Table 2) , and exclusions of twins/multiples did not alter this (data not shown). AML cases were more likely than controls to have a birth order of third or higher. The mean age of control mothers at birth was slightly younger [27.0 (SD = 5. In multivariate analyses of complete records, we did not observe associations between maternal age and infant leukaemia overall (Figure 1a) or ALL, although point estimates for the risk of ALL were decreased for mothers age ≤19 years and 20-24 years (Figure 1b) . Older maternal age was associated with increased point estimates for risk of infant AML in our complete records analysis, and we observed a strong estimated effect for AML in relation to maternal age ≥40 years (OR 4.80, 95% CI 1.80, 12.76; Figure 1c) . This association remained when we used imputed parental ages (OR 4.27, 95% CI 1.72, 10.64; Table S1 ).
In complete records analyses of paternal age, very young paternal age (≤19 years) was associated with infant leukaemia overall (Figure 2a) , with a particularly strong effect estimate for infant ALL (Figure 2b) . This association was somewhat attenuated with imputed parental ages (Table S2 ). The estimated effect for paternal age 20-24 years and infant ALL was also increased in our complete records analysis. Also using complete records for analysis, we did not observe an association between advanced paternal age and infant ALL, and there was no association between either younger or advanced paternal age and infant AML (Figure 2c) .
Sensitivity analyses excluding births prior to 1989 from Washington and bias analysis to assess the effect of under ascertainment of Down's syndrome cases did not change the results (data not shown). Analyses stratified by infant's age at diagnosis yielded generally similar results but were based on very few numbers of cases in the extremes of the parental age spectrum (data not shown). 
Comment

Main findings
We observed associations between older maternal age and infant AML and younger paternal age and infant ALL. These results remained consistent both when we used imputed parental ages and conducted sensitivity analyses limiting to mothers' age 16 years and older.
Interpretation
Although several studies have investigated the relationship between parental age and childhood cancer, few previous studies have examined infant leukaemia specifically. One analysis which combined data from three population-based case-control studies investigated maternal age among all infant leukaemias (ALL and AML combined, n = 303) reported a suggestive u-shaped relationship, where offspring of both younger and older mothers had increased risk of infant leukaemia compared to mothers age 20-35 years. 15 Another population-based case-control study did not find an association between maternal age and all infant leukaemias (ALL and AML, n = 238). 16 Neither of these analyses accounted for paternal age or stratified by leukaemia subtype, which may explain the inconsistency of these results compared to our study; also both relied on active participation and may have been susceptible to selection bias. A recent meta-analysis of parental age and childhood leukaemia showed associations between both younger and older maternal age and childhood AML and young paternal age and childhood AML. 17 However, the comparability of the meta-analysis to this study is limited due to inclusion of children diagnosed at older ages, variation between studies on classification of parental age categories, and the fact that only a subset of included studies mutually adjusted for maternal and paternal age. The mechanisms through which advanced maternal age could affect infant leukaemia risk might include aberrant gene expression or genomic alterations. Maternal age is known to play an important role in the aetiology of other offspring outcomes involving chromosomal anomalies; 18 given the importance of the MLL rearrangements in infant leukaemia, it is possible that maternal age plays a role in these novel mutational events. Furthermore, de novo point mutations increase with maternal age, 19 and these maternally derived mutational signatures may be distinct from those that are paternally derived. A prior study has reported that germline variation may play an important role in infant leukaemia without MLL translocations, with a particularly striking association between variations in the MLL3 gene among AML cases. 8 Interestingly, in that study, 38% (5 of 13) of mothers of AML cases were >35 years of age. Given that the gene regulatory functions of the MLL family of proteins rely on histone modification with known histone methyltransferase functions and suspected histone ubiquitination functions, epigenetic alterations in oocytes that are transmissible to offspring are another possible mechanism. Studies in both humans 20 and mice 21 have demonstrated age-associated differential gene expression in oocytes among cell cycle control and DNA repair pathways. Furthermore, several studies have reported aberrant methylation patterns in infant leukaemia, 22 including a study within a mouse model of MLL-rearranged leukaemia. 23 It is also possible that a longer period of cumulative exposure to environmental mutagens in older mothers also plays a role. Environmental toxins have been shown to induce global hypermethylation, de novo germline mutations, and DNA damage in germ cells, and can have longterm developmental effects in offspring. 24 Older mothers are more likely to have used assisted reproductive technology (ART) 25 and fertility treatment has been implicated as a possible cause of childhood cancer among offspring. 26 While we did not have information on use of fertility treatments, we do not believe that this contributed significantly to our findings as there are very few twins and higher-order multiples among our cases (n = 6). Although in the last two decades efforts have been made within the medical community to reduce the number of multiple births resulting from ART, our study covers birth years prior to most of these efforts, when nearly 60% of livebirths from ART were twin gestations or higher-order multiples. 27 It is also possible that older maternal age is a proxy for other factors that could increase risk of infant leukaemia in the offspring, such as age-associated changes in hormonal levels during pregnancy. 28 The mechanisms through which young paternal age could affect infant leukaemia risk are less clear, although adverse outcomes among offspring of young fathers, including an increased risk of chromosomal aneuploidies, 29 schizophrenia, 30 preterm birth, 31 and birth defects 32 have been reported. A recent study reported a 6.7-fold increase in germline mutation rate for teenage fathers compared to teenage mothers. 33 From this mutation rate among young fathers, the authors estimated that approximately 147 cell divisions may occur in the male germline during prepuberty spermatogenesis, which is much higher than previously estimated. Therefore, there may be a high burden of de novo germline mutations among offspring of young fathers which could account for the excess risk observed in these children. Furthermore, young men with drug and other substance abuse problems are more likely to become teenage fathers, 34 and these behaviours are also associated with increased germline mutations in sperm and other deleterious effects in spermatozoa. 35 We were not able to exclude children with Down's syndrome for early birth years from Washington state, although sensitivity analysis excluding years in which birth records did not record Down's syndrome did not change our results. However, birth certificates may not capture all cases of Down's syndrome even when it is recorded. As children with Down's syndrome are predisposed to leukaemia 36 Strengths of the study Strengths of our study include the population-based data and use of high-quality cancer registries to ascertain cases and birth registries from which we randomly sampled controls. The large sample size allowed stratification of infant leukaemia subtype and also provided sufficient power to detect associations among the two extremes of the parental age spectrum. Our study did not rely on active participation and therefore selection bias is not expected to have impacted our results. We expect that our main exposure variable, parental age, is accurately reported on birth certificates.
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Limitations of the data Misclassification of other covariates is possible, however, any misclassification would be nondifferential with respect to disease status and therefore would bias estimates towards the null. Although this study did not include infant leukaemia cases from the entire US population, we expect that the results are generalizable to all infant leukaemias in the US given that this was a population-based sample and we do not believe the factors that distinguish the study population from the general US population modify the effect of parental age on risk of infant leukaemia. Furthermore, the racial and ethnic diversity of controls mirrors that of the US as a whole, and the maternal and paternal ages of controls follow national trends from the past three decades. Paternal age was missing in 10.9% of records for mothers age >16 years and 41.4% of those for mothers age ≤16 years. We accounted for this by imputation for parental ages and by performing a sensitivity analysis, excluding children whose mothers were age ≤16 years; associations were slightly attenuated using imputation methods, but remained statistically significant. Our study was limited by lack of data available on other variables of interest, such as MLL rearrangement status, use of ART, and complete ascertainment of Down's syndrome.
Conclusions
Our results suggest associations between advanced maternal age and risk of infant AML and young paternal age and risk of infant ALL. As most aetiological studies of infant leukaemia focus on pregnancyrelated events, our results suggest that future studies need to consider both maternal and paternal contributions. In particular, parent of origin de novo mutations and/or carcinogenic exposures may be involved. In addition, future studies on whether these results vary by MLL status or use of ART will be useful for a thorough analysis of these potential associations.
